SG11201810177VA - Pet-imaging immunomodulators - Google Patents
Pet-imaging immunomodulatorsInfo
- Publication number
- SG11201810177VA SG11201810177VA SG11201810177VA SG11201810177VA SG11201810177VA SG 11201810177V A SG11201810177V A SG 11201810177VA SG 11201810177V A SG11201810177V A SG 11201810177VA SG 11201810177V A SG11201810177V A SG 11201810177VA SG 11201810177V A SG11201810177V A SG 11201810177VA
- Authority
- SG
- Singapore
- Prior art keywords
- bristol
- international
- princeton
- route
- myers squibb
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 3
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/12—Arrangements for detecting or locating foreign bodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- High Energy & Nuclear Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111111111111111111111111111111111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/201111 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, A61K 51/08 (2006.01) A61K 101/02 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2017/033004 HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 17 May 2017 (17.05.2017) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/338,872 19 May 2016 (19.05.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, [US/US]; Route 206 and Province Line Road, Princeton, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, New Jersey 08543 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (72) Inventors: DONNELLY, David J.; c/o Bristol-Myers TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Squibb Company, Route 206 and Province Line Road, KM, ML, MR, NE, SN, TD, TG). Princeton, New Jersey 08543 (US). BOY, Kenneth M.; _ c/o Bristol-Myers Squibb Company, 5 Research Parkway, Declarations under Rule 4.17: Wallingford, Connecticut 06492 (US). ZHANG, Yun- — as to applicant's entitlement to apply for and be granted a hui; c/o Bristol-Myers Squibb Company, 5 Research Park- patent (Rule 4. 17(ii)) = way, Wallingford, Connecticut 06492 (US). KIM, Joony- — as to the applicant's entitlement to claim the priority of the = — oung; c/o Bristol-Myers Squibb Company, Route 206 and earlier application (Rule 4.17(iii)) Province Line Road, Princeton, New Jersey 08543 (US). — of inventorship (Rule 4.17(iv)) — = PENA, Adrienne; c/o Bristol-Myers Squibb Company, Published: Route 206 and Province Line Road, Princeton, New Jersey — with international search report (Art. 21(3)) 08543 (US). = (74) Agent: MINGO, Pamela A. et al.; Bristol-Myers Squibb _ Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). — = Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, = = = (54) Title: PET-IMAGING IMMUNOMODULATORS = = = SUV = Fp- = ..,.• t Il 11 11 © N 60 FIG . 1 , IN ,-1 © ei (57) : The invention relates to the synthesis and use of 18 F-labeled millamolecules for imaging various processes within the P1 body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338872P | 2016-05-19 | 2016-05-19 | |
| PCT/US2017/033004 WO2017201111A1 (en) | 2016-05-19 | 2017-05-17 | Pet-imaging immunomodulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810177VA true SG11201810177VA (en) | 2018-12-28 |
Family
ID=59021563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810177VA SG11201810177VA (en) | 2016-05-19 | 2017-05-17 | Pet-imaging immunomodulators |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11103605B2 (en) |
| EP (2) | EP3458111B1 (en) |
| JP (1) | JP6953444B2 (en) |
| KR (1) | KR102378288B1 (en) |
| CN (1) | CN109414514B (en) |
| AU (1) | AU2017268291B2 (en) |
| BR (1) | BR112018073642A2 (en) |
| CA (1) | CA3024844A1 (en) |
| CY (1) | CY1124241T1 (en) |
| DK (1) | DK3458111T3 (en) |
| EA (1) | EA038019B1 (en) |
| ES (1) | ES2864091T3 (en) |
| HR (1) | HRP20210644T8 (en) |
| HU (1) | HUE054306T2 (en) |
| IL (1) | IL262962B (en) |
| LT (1) | LT3458111T (en) |
| MA (1) | MA53402A (en) |
| MX (1) | MX2018014028A (en) |
| PL (1) | PL3458111T3 (en) |
| PT (1) | PT3458111T (en) |
| RS (1) | RS61742B1 (en) |
| SG (1) | SG11201810177VA (en) |
| SI (1) | SI3458111T1 (en) |
| WO (1) | WO2017201111A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| CA3045466A1 (en) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| MX2019007615A (en) * | 2016-12-23 | 2019-11-05 | Univ Johns Hopkins | Tumor and immune cell imaging based on pd-l1 expression. |
| SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| KR20200020858A (en) | 2017-06-23 | 2020-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Immunomodulators Acting as Antagonists of PD-1 |
| CA3070796A1 (en) | 2017-07-24 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Anti-cd8 antibodies and uses thereof |
| KR20200058506A (en) | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | Immunomodulators |
| CN110504017B (en) * | 2019-07-30 | 2022-06-10 | 哈尔滨医科大学 | Preparation and application method of tracer |
| CN115485288A (en) * | 2020-03-16 | 2022-12-16 | 百时美施贵宝公司 | Immunomodulator |
| US20220405917A1 (en) * | 2021-06-18 | 2022-12-22 | Case Western Reserve University | Combination of features from biopsies and scans to predict prognosis in sclc |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (en) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | LIPOSOMAS COUPLING METHOD. |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5328679A (en) | 1988-04-01 | 1994-07-12 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of proteins |
| US5128119A (en) | 1989-06-12 | 1992-07-07 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of f(ab1)2 fragments |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| IL113610A0 (en) | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
| US5746996A (en) | 1994-06-03 | 1998-05-05 | Immunomedics, Inc. | Thiolation of peptides for radionuclide-based radiodetection and radiotherapy |
| US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| WO1997041898A1 (en) | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| WO1998002192A1 (en) | 1996-07-12 | 1998-01-22 | Immunomedics, Inc. | Radiometal-binding peptide analogues |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| WO1999011590A1 (en) | 1997-09-03 | 1999-03-11 | Immunomedics, Inc. | Fluorination of proteins and peptides for f-18 positron emission tomography |
| US9090668B2 (en) | 2007-03-26 | 2015-07-28 | The University Of Tokyo | Process for synthesizing cyclic peptide compound |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (en) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Translational construction and search for active species of special peptide compound library containing N-methylamino acid and other special amino acids |
| JP6206943B2 (en) | 2010-12-03 | 2017-10-04 | 国立大学法人 東京大学 | Method for producing peptide library, peptide library, and screening method |
| WO2013010573A1 (en) * | 2011-07-18 | 2013-01-24 | Universitaet Muenster | Compounds with matrix-metalloproteinase inhibitory activity |
| EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| AU2013239366A1 (en) | 2012-03-29 | 2014-10-16 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the BC loop of human PD1 |
| JP2013253842A (en) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | Screening method for peptide connected to target molecule depending on ph |
| IN2014KN02752A (en) | 2012-06-06 | 2015-05-08 | Polyphor Ag | |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| CA2905798C (en) | 2013-03-15 | 2023-01-24 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| JP6474412B2 (en) | 2013-09-06 | 2019-02-27 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Cyclic peptidomimetic compounds as immunomodulators |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| TN2017000084A1 (en) | 2014-09-11 | 2018-07-04 | Bristol Myers Squibb Co | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| BR112017010414A2 (en) | 2014-11-25 | 2018-05-15 | Bristol-Myers Squibb Company | methods and compositions for 18f radiolabeling of biological substances |
| EA037590B1 (en) | 2014-11-25 | 2021-04-19 | Бристол-Майерс Сквибб Компани | PD-L1 BINDING POLYPEPTIDES COMPRISING 10Fn3 DOMAIN FOR IMAGING |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| US10988507B2 (en) | 2016-11-07 | 2021-04-27 | Bristol-Myers Squibb Company | Immunomodulators |
| KR20200020858A (en) | 2017-06-23 | 2020-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Immunomodulators Acting as Antagonists of PD-1 |
| KR20200058506A (en) | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | Immunomodulators |
-
2017
- 2017-05-17 LT LTEP17728696.0T patent/LT3458111T/en unknown
- 2017-05-17 WO PCT/US2017/033004 patent/WO2017201111A1/en unknown
- 2017-05-17 AU AU2017268291A patent/AU2017268291B2/en active Active
- 2017-05-17 JP JP2018560588A patent/JP6953444B2/en active Active
- 2017-05-17 HU HUE17728696A patent/HUE054306T2/en unknown
- 2017-05-17 BR BR112018073642-2A patent/BR112018073642A2/en unknown
- 2017-05-17 MA MA053402A patent/MA53402A/en unknown
- 2017-05-17 CA CA3024844A patent/CA3024844A1/en active Pending
- 2017-05-17 PL PL17728696T patent/PL3458111T3/en unknown
- 2017-05-17 PT PT177286960T patent/PT3458111T/en unknown
- 2017-05-17 EP EP17728696.0A patent/EP3458111B1/en active Active
- 2017-05-17 EP EP21152813.8A patent/EP3827849A1/en active Pending
- 2017-05-17 SG SG11201810177VA patent/SG11201810177VA/en unknown
- 2017-05-17 KR KR1020187036396A patent/KR102378288B1/en active IP Right Grant
- 2017-05-17 SI SI201730690T patent/SI3458111T1/en unknown
- 2017-05-17 US US16/098,765 patent/US11103605B2/en active Active
- 2017-05-17 RS RS20210499A patent/RS61742B1/en unknown
- 2017-05-17 DK DK17728696.0T patent/DK3458111T3/en active
- 2017-05-17 EA EA201892635A patent/EA038019B1/en unknown
- 2017-05-17 MX MX2018014028A patent/MX2018014028A/en unknown
- 2017-05-17 ES ES17728696T patent/ES2864091T3/en active Active
- 2017-05-17 CN CN201780042462.1A patent/CN109414514B/en active Active
-
2018
- 2018-11-12 IL IL262962A patent/IL262962B/en active IP Right Grant
-
2021
- 2021-04-23 HR HRP20210644TT patent/HRP20210644T8/en unknown
- 2021-04-29 CY CY20211100375T patent/CY1124241T1/en unknown
- 2021-08-26 US US17/412,612 patent/US20210386876A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |